Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

289 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis.
Tang A, Ng CH, Phang PH, Chan KE, Chin YH, Fu CE, Zeng RW, Xiao J, Tan DJH, Quek J, Lim WH, Mak LY, Wang JW, Chew NWS, Syn N, Huang DQ, Siddiqui MS, Sanyal A, Muthiah M, Noureddin M. Tang A, et al. Among authors: noureddin m. Clin Gastroenterol Hepatol. 2023 Jul;21(7):1750-1760.e12. doi: 10.1016/j.cgh.2022.06.029. Epub 2022 Jul 19. Clin Gastroenterol Hepatol. 2023. PMID: 35863685 Review.
Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis.
Han MAT, Altayar O, Hamdeh S, Takyar V, Rotman Y, Etzion O, Lefebvre E, Safadi R, Ratziu V, Prokop LJ, Murad MH, Noureddin M. Han MAT, et al. Among authors: noureddin m. Clin Gastroenterol Hepatol. 2019 Mar;17(4):616-629.e26. doi: 10.1016/j.cgh.2018.06.011. Epub 2018 Jun 18. Clin Gastroenterol Hepatol. 2019. PMID: 29913275
Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts.
Mayo R, Crespo J, Martínez-Arranz I, Banales JM, Arias M, Mincholé I, Aller de la Fuente R, Jimenez-Agüero R, Alonso C, de Luis DA, Vitek L, Stritesky J, Caballería J, Romero-Gómez M, Martín-Duce A, Mugüerza Huguet JM, Busteros-Moraza JI, Idowu MO, Castro A, Martínez-Chantar ML, Ortiz P, Bruha R, Lu SC, Bedossa P, Noureddin M, Sanyal AJ, Mato JM. Mayo R, et al. Among authors: noureddin m. Hepatol Commun. 2018 May 4;2(7):807-820. doi: 10.1002/hep4.1188. eCollection 2018 Jul. Hepatol Commun. 2018. PMID: 30027139 Free PMC article.
Pathogenesis of NASH: The Impact of Multiple Pathways.
Noureddin M, Sanyal AJ. Noureddin M, et al. Curr Hepatol Rep. 2018 Dec;17(4):350-360. doi: 10.1007/s11901-018-0425-7. Epub 2018 Oct 31. Curr Hepatol Rep. 2018. PMID: 31380156 Free PMC article.
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, Shiffman ML, Camargo M, Li G, Kersey K, Jia C, Zhu Y, Djedjos CS, Subramanian GM, Myers RP, Gunn N, Sheikh A, Anstee QM, Romero-Gomez M, Trauner M, Goodman Z, Lawitz EJ, Younossi Z; STELLAR-3; STELLAR-4 Investigators. Harrison SA, et al. J Hepatol. 2020 Jul;73(1):26-39. doi: 10.1016/j.jhep.2020.02.027. Epub 2020 Mar 6. J Hepatol. 2020. PMID: 32147362 Clinical Trial.
289 results